MassDevice.com looked at some of the most talked-about medical device companies, based on trends in U.S. Google searches for the last 30 days.
Boston Scientific
MassDevice.com +3 | The top 3 med-tech stories for July 2, 2012
Say hello to MassDevice +3, a bite-sized view of the top three med-tech stories of the day. This feature of MassDevice.com’s coverage highlights our 3 biggest and most influential stories from the day’s news to make sure you’re up to date on the headlines that continue to shape the medical device industry.
If you read nothing else today, make sure you’re still in the know with MassDevice +3.
Boston Scientific closes enrollment in Watchman trial
Boston Scientific (NYSE:BSX) said today that it’s closed enrollment for the Prevail study of its Watchman heart implant with a final burst of 407 patients across 42 sites.
The randomized trial will support the medical device company’s bid for FDA clearance, but BSX will need to gather 6 months of data before submitting its application.
MassDevice.com +7 | The top 7 med-tech stories for the week of June 25, 2012
Say hello to MassDevice +7, a bite-sized view of the top seven med-tech stories of the week. This latest feature of MassDevice.com’s coverage highlights our seven biggest and most influential stories from the week’s news to make sure you’re up to date on the headlines that continue to shape the medical device industry.
If you read nothing else this weekend, make sure you’re still in the know with MassDevice +7.
MassDevice.com +3 | The top 3 med-tech stories for June 27, 2012
Say hello to MassDevice +3, a bite-sized view of the top three med-tech stories of the day. This feature of MassDevice.com’s coverage highlights our 3 biggest and most influential stories from the day’s news to make sure you’re up to date on the headlines that continue to shape the medical device industry.
If you read nothing else today, make sure you’re still in the know with MassDevice +3.
Boston Scientific sells Prolieve device back to Medifocus for $5M
Updated June 28, 2012, at 12:45 p.m. with comments from Medifocus.
Medical device titan Boston Scientific (NYSE:BSX) sold the Prolieve business back to Medifocus (PINK:MDFZF) in a deal valued at $5 million.
FDA user fee bill heads to the White House | MassDevice.com On Call
MASSDEVICE ON CALL — The U.S. Senate last night voted 92-4 to approve the latest iteration of the Medical Device User Fee & Modernization Act, which was bundled in a larger FDA user fee measure.
Lawmakers agreed to push forward the bill, which will now head to the White House for a signature from President Barack Obama before becoming law.
Boston Scientific nabs former J&J China manager | Personnel Moves
MassDevice.com +7 | The top 7 med-tech stories for the week of June 11, 2012
Say hello to MassDevice +7, a bite-sized view of the top seven med-tech stories of the week. This latest feature of MassDevice.com’s coverage highlights our seven biggest and most influential stories from the week’s news to make sure you’re up to date on the headlines that continue to shape the medical device industry.
If you read nothing else this weekend, make sure you’re still in the know with MassDevice +7.
Some thoughts on the subcutaneous implantable cardiac defibrillator
Boston Scientific’s next-gen wireless heart implant monitoring keeps patients out of the office
Boston Scientific (NYSE:BSX) unveiled its next-generation Latitude NXT patient monitoring system in Europe this week, implanting the 1st patient with an Ingenio pacemaker designed to connect with a home-based wireless communicator that can tie in data from blood pressure readings as well as a weight scale.